News from spherix global insights A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 30, 2022, 10:00 ET High Unmet Needs Remain in Nephrology Despite Newly Approved Treatment Options According to Latest Research from Spherix Global Insights

A survey of 124 US nephrologists, conducted just last week, identifies acute kidney injury (AKI), diabetic kidney disease (DKD), and polycystic...

Jun 29, 2022, 04:00 ET European Nephrologists Lead the Way with Adoption of Astellas/FibroGen's HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings, Spherix Report Finds

The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel HIF-PH...

Jun 24, 2022, 08:00 ET US Dermatologists' Lack of Success with Current Treatment Options in Vitiligo Paves the Way for Pipeline Advanced Systemic Agents to Disrupt the Market, According to Spherix Global Insights

Vitiligo is a disease that causes loss of skin color in patches when cells that produce melanin die or stop functioning.1 Spherix recently surveyed...

Jun 22, 2022, 15:13 ET New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly's Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights

Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative...

Jun 17, 2022, 06:20 ET Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis

With the approvals of GlaxoSmithKline's Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia's Lupkynis at the beginning of 2021,...

Jun 16, 2022, 08:00 ET New Spherix Study Reveals Jardiance (Lilly/Boehringer Ingelheim) Has Potential to Challenge Farxiga (AstraZeneca) Lead Among the Non-Diabetic CKD Population

As the chronic kidney disease (CKD) and diabetic kidney disease (DKD) treatment landscapes rapidly evolve, nephrologists are providing important...

Jun 16, 2022, 06:30 ET Spherix Global Insights Will Begin Tracking the Launch of Sanofi/Regeneron's Dupixent for the Treatment of Eosinophilic Esophagitis

On May 20, 2022, the FDA approved Sanofi/Regeneron's Dupixent, the first therapy indicated to treat eosinophilic esophagitis (EoE). In response,...

Jun 14, 2022, 04:00 ET Novartis' Cosentyx and Eli Lilly's Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen's Tremfya and AbbVie's Skyrizi Are Picking Up Steam, Spherix Reports

Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several...

Jun 10, 2022, 07:00 ET Biohaven's Nurtec ODT and AbbVie's Qulipta Emerging as the Top Two Contenders in the Preventive Migraine Space, According to Spherix Global Insights

According to the latest deep dive report included in Spherix's Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists...

Jun 09, 2022, 12:01 ET Vyvgart's Novel Mechanism of Action and Efficacy Are Top Advantages of the Brand, According to Neurologists Surveyed by Spherix Global Insights

Three months into the launch of argenx's Vyvgart for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody...

Jun 08, 2022, 12:00 ET Nephrologists Await Advanced Pipeline Agents, Including Venglustat (Sanofi), Lucerastat (Idorsia), and PRX-102 (Protalix), to Address High Unmet Need in Fabry Disease, Spherix Reports

Fabry disease is an extremely rare genetic condition most prevalent in men and potentially underdiagnosed in women. Nephrologists rank it as one of...

Jun 08, 2022, 07:00 ET Changes Afoot in US Age-Related Macular Degeneration Market as Prescribers Brace for the Launch of Biogen and Samsung Bioepis' Byooviz, According to Spherix Global Insights

After several years of lackluster reception towards off-label biosimilar, Genentech's Avastin (bevacizumab), ophthalmologists have finally seen the...

Jun 07, 2022, 16:35 ET Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology

Fellows will be the next generation of practitioners. Most academic institutions have closed-door policies for industry, leaving a large gap in...

Jun 07, 2022, 10:11 ET AbbVie's Rinvoq Already Flexing Its Promotional and Efficacy Muscles to Impact the Ulcerative Colitis Market, According to Spherix Global Insights

According to the latest deep dive report published as part of Spherix's Launch Dynamix™: Rinvoq in Ulcerative Colitis (US) service, AbbVie's...

Jun 02, 2022, 13:03 ET Spherix Global Insights Announces Entry into Asia-Pacific Research with Upcoming IgA Nephropathy Market and Pipeline Assessment in Japan

Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger's disease,...

Jun 01, 2022, 07:30 ET Diabetes-Related Mechanisms of Action Make Their Move as Several NAFLD/NASH Pipeline Therapies Inch Closer to the First-Ever FDA Approval, Spherix Reports

Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 ...

May 26, 2022, 15:50 ET Novartis' Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada According to Surveyed Neurologists in Spherix Report

Following an eventful 2021 that included the launch of two new brands—Novartis' Kesimpta and BMS' Zeposia—and generic versions of Biogen's Tecfidera, ...

May 16, 2022, 07:30 ET Neurologists React to CMS' Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease

On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer's disease. Given the importance...

May 12, 2022, 08:00 ET Spherix Global Insights Identifies Significant Unmet Need and Strong Opportunity for a Newly Launched Mechanism of Action in IBS-C Market

Spherix recently surveyed 102 gastroenterologists and 100 primary care physicians (PCPs), including eight qualitative interviews with...

Apr 27, 2022, 13:08 ET Spherix Global Insights Announces Exhibition and Releases the Title of Their Abstract to be Presented at the 2022 ARVO Annual Meeting

At the beginning of this year, Spherix Global Insights, a leading market intelligence firm, expanded their coverage of select specialty markets with...

Apr 25, 2022, 04:00 ET Spherix Uncovers Key Differences in the Management of Chronic Kidney Disease Patients in Europe Versus the U.S.

The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their...

Apr 11, 2022, 07:00 ET New Spherix Research Suggests Rheumatologists Are Gravitating Towards BMS' Orencia for the Treatment of Rheumatoid Arthritis as JAK Inhibitor Use Declines

The US rheumatoid arthritis (RA) biologic and small molecule market has remained relatively stagnant over the past few years, with little change in...

Apr 05, 2022, 06:00 ET Novartis' Kesimpta is Poised for Strong Growth in the European Multiple Sclerosis Market, Spherix Global Insights Reports

Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple...

Mar 28, 2022, 07:30 ET IgA Nephropathy Market Shakes Up with Tarpeyo (Calliditas) Launch and Surge in Physician Prescribing of SGLT2 Inhibitors, Spherix Reports

IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting...

Mar 23, 2022, 07:30 ET Could Microbiome-Based Therapeutics Fill the Unmet Need in Recurrent Clostridioides Difficile (C. Diff) Treatment? Spherix Investigates

Spherix recently surveyed 76 gastroenterologists and 26 infectious disease (ID) physicians (including 8 qualitative interviews between both...